Celularity Inc.: insider trading
130 trades by 25 directors, officers and 10% owners since 2021, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$0
0 sales by 0 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$0
0 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Too few open-market trades to chart.
Insiders (25)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| John R. HainesSenior Exec Vice President | 30,179 | — | — | |
| Robert J. HaririChief Executive Officer, Director | 2.85 M | — | — | |
| Stephen BrigidoPres., Functional Regeneration | 9,474 | — | — | |
| Diane L. ParksDirector | 520,021 | — | — | |
| Geoffrey LingDirector | 256,026 | — | — | |
| Peter DiamandisDirector | 394,150 | — | — | |
| Vincent LeVienDirector | 153,847 | — | — | |
| David C. BeersChief Financial Officer | 18,201 | — | — | |
| Berhad Genting10% owner | — | — | — | |
| Dean C. KehlerDirector | 303,482 | — | — | |
| Richard J. BermanDirector | 67,416 | — | — | |
| Kyle FletcherSee Remarks | 21,085 | — | — | |
| Adrian KilcoyneChief Medical Officer | 1.12 M | — | — | |
| Sorrento Therapeutics, Inc.10% owner | 5.05 M | — | — | |
| Andrew C. Von EschenbachDirector | 336,066 | — | — | |
| John SculleyDirector | 1.00 M | — | — | |
| Kok Thay LimDirector | 225,222 | — | — | |
| Marc MazurDirector | 236,066 | — | — | |
| Robin L. SmithDirector | 236,066 | — | — | |
| Bradley GloverSee Remarks | 351,192 | — | — | |
| Anne JonesChief Business Officer | 49,154 | — | — | |
| Keary DunnSee Remarks | 16,405 | — | — | |
| Starr International Co Inc10% owner | — | — | — | |
| GX Sponsor LLC10% owner | 100,000 | — | — | |
| Jay R. BloomDirector | — | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Berhad Genting10% owner | Buyindirect | +21.41 M | $0.250 | $5.4 M | 51.47 M | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Buy | +6.31 M | $0.160 | $1.0 M | 25.52 M | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Buy | +3.05 M | $0.160 | $488 K | 28.57 M | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Buy | +9.06 M | $0.170 | $1.5 M | 19.21 M | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Buy | +10,000 | $1.720 | $17 K | 8.07 M | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Buy | +40,000 | $1.710 | $68 K | 8.06 M | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Buy | +40,000 | $1.740 | $70 K | 8.02 M | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice